SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis

FRA:SRT3 • DE0007165631

224.6 EUR
-15.7 (-6.53%)
Last: Mar 3, 2026, 05:29 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

SRT3 gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 18 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of SRT3 have multiple concerns. SRT3 is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year SRT3 was profitable.
  • In the past year SRT3 had a positive cash flow from operations.
  • SRT3 had positive earnings in 4 of the past 5 years.
  • Of the past 5 years SRT3 4 years had a positive operating cash flow.
SRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFSRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 1.39%, SRT3 is doing worse than 77.78% of the companies in the same industry.
  • SRT3 has a Return On Equity of 5.01%. This is in the lower half of the industry: SRT3 underperforms 72.22% of its industry peers.
  • The Return On Invested Capital of SRT3 (4.71%) is worse than 77.78% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for SRT3 is in line with the industry average of 9.64%.
Industry RankSector Rank
ROA 1.39%
ROE 5.01%
ROIC 4.71%
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
SRT3.DE Yearly ROA, ROE, ROICSRT3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • With a Profit Margin value of 3.80%, SRT3 is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
  • In the last couple of years the Profit Margin of SRT3 has declined.
  • SRT3 has a Operating Margin (14.06%) which is comparable to the rest of the industry.
  • SRT3's Operating Margin has declined in the last couple of years.
  • SRT3's Gross Margin of 46.48% is fine compared to the rest of the industry. SRT3 outperforms 66.67% of its industry peers.
  • In the last couple of years the Gross Margin of SRT3 has declined.
Industry RankSector Rank
OM 14.06%
PM (TTM) 3.8%
GM 46.48%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
SRT3.DE Yearly Profit, Operating, Gross MarginsSRT3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • SRT3 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • There is no outstanding debt for SRT3. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SRT3.DE Yearly Shares OutstandingSRT3.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SRT3.DE Yearly Total Debt VS Total AssetsSRT3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • SRT3 has an Altman-Z score of 2.42. This is not the best score and indicates that SRT3 is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of SRT3 (2.42) is comparable to the rest of the industry.
  • The Debt to FCF ratio of SRT3 is 8.92, which is on the high side as it means it would take SRT3, 8.92 years of fcf income to pay off all of its debts.
  • SRT3 has a worse Debt to FCF ratio (8.92) than 66.67% of its industry peers.
  • A Debt/Equity ratio of 1.28 is on the high side and indicates that SRT3 has dependencies on debt financing.
  • SRT3 has a worse Debt to Equity ratio (1.28) than 77.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF 8.92
Altman-Z 2.42
ROIC/WACC0.57
WACC8.31%
SRT3.DE Yearly LT Debt VS Equity VS FCFSRT3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

  • SRT3 has a Current Ratio of 0.95. This is a bad value and indicates that SRT3 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • SRT3's Current ratio of 0.95 is on the low side compared to the rest of the industry. SRT3 is outperformed by 83.33% of its industry peers.
  • SRT3 has a Quick Ratio of 0.95. This is a bad value and indicates that SRT3 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.49, SRT3 is doing worse than 88.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.49
SRT3.DE Yearly Current Assets VS Current LiabilitesSRT3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • SRT3 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 1.76% yearly.
EPS 1Y (TTM)N/A
EPS 3Y-20.66%
EPS 5Y1.76%
EPS Q2Q%21.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.29%

3.2 Future

  • SRT3 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.97% yearly.
  • Based on estimates for the next years, SRT3 will show a quite strong growth in Revenue. The Revenue will grow by 8.68% on average per year.
EPS Next Y26.59%
EPS Next 2Y23.47%
EPS Next 3Y20.79%
EPS Next 5Y15.97%
Revenue Next Year7.13%
Revenue Next 2Y8.81%
Revenue Next 3Y9.38%
Revenue Next 5Y8.68%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SRT3.DE Yearly Revenue VS EstimatesSRT3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
SRT3.DE Yearly EPS VS EstimatesSRT3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 46.99 indicates a quite expensive valuation of SRT3.
  • Based on the Price/Earnings ratio, SRT3 is valued expensively inside the industry as 83.33% of the companies are valued cheaper.
  • When comparing the Price/Earnings ratio of SRT3 to the average of the S&P500 Index (26.83), we can say SRT3 is valued expensively.
  • Based on the Price/Forward Earnings ratio of 37.12, the valuation of SRT3 can be described as expensive.
  • Based on the Price/Forward Earnings ratio, SRT3 is valued a bit more expensive than 77.78% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 24.95. SRT3 is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 46.99
Fwd PE 37.12
SRT3.DE Price Earnings VS Forward Price EarningsSRT3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, SRT3 is valued a bit more expensive than 66.67% of the companies in the same industry.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as SRT3.
Industry RankSector Rank
P/FCF 35.14
EV/EBITDA 23.61
SRT3.DE Per share dataSRT3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • SRT3's earnings are expected to grow with 20.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.77
PEG (5Y)26.65
EPS Next 2Y23.47%
EPS Next 3Y20.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • SRT3 has a yearly dividend return of 0.38%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.44, SRT3 pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.82, SRT3's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.38%

5.2 History

  • The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 37.92% of the earnings are spent on dividend by SRT3. This is a low number and sustainable payout ratio.
  • SRT3's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP37.92%
EPS Next 2Y23.47%
EPS Next 3Y20.79%
SRT3.DE Yearly Income VS Free CF VS DividendSRT3.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
SRT3.DE Dividend Payout.SRT3.DE Dividend Payout, showing the Payout Ratio.SRT3.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

SARTORIUS AG-VORZUG

FRA:SRT3 (3/3/2026, 5:29:49 PM)

224.6

-15.7 (-6.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)04-23
Inst Owners4.42%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.82B
Revenue(TTM)N/A
Net Income(TTM)133.70M
Analysts80
Price Target376.45 (67.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.38%
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP37.92%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.85%
Min EPS beat(2)-10.52%
Max EPS beat(2)4.83%
EPS beat(4)1
Avg EPS beat(4)-3.47%
Min EPS beat(4)-10.52%
Max EPS beat(4)4.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.05%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)0.83%
Revenue beat(4)3
Avg Revenue beat(4)1.91%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.73%
PT rev (3m)9.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.96%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)-0.03%
Valuation
Industry RankSector Rank
PE 46.99
Fwd PE 37.12
P/S 4.78
P/FCF 35.14
P/OCF 19.24
P/B 6.3
P/tB N/A
EV/EBITDA 23.61
EPS(TTM)4.78
EY2.13%
EPS(NY)6.05
Fwd EY2.69%
FCF(TTM)6.39
FCFY2.85%
OCF(TTM)11.68
OCFY5.2%
SpS46.97
BVpS35.63
TBVpS-35.24
PEG (NY)1.77
PEG (5Y)26.65
Graham Number61.91
Profitability
Industry RankSector Rank
ROA 1.39%
ROE 5.01%
ROCE 6.33%
ROIC 4.71%
ROICexc 4.98%
ROICexgc 17.77%
OM 14.06%
PM (TTM) 3.8%
GM 46.48%
FCFM 13.61%
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexgc growth 3Y-35.26%
ROICexgc growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF 8.92
Debt/EBITDA 3.69
Cap/Depr 92.32%
Cap/Sales 11.25%
Interest Coverage 2.65
Cash Conversion 94.72%
Profit Quality 357.97%
Current Ratio 0.95
Quick Ratio 0.49
Altman-Z 2.42
F-Score7
WACC8.31%
ROIC/WACC0.57
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3Y-20.66%
EPS 5Y1.76%
EPS Q2Q%21.15%
EPS Next Y26.59%
EPS Next 2Y23.47%
EPS Next 3Y20.79%
EPS Next 5Y15.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.29%
Revenue Next Year7.13%
Revenue Next 2Y8.81%
Revenue Next 3Y9.38%
Revenue Next 5Y8.68%
EBIT growth 1Y18.65%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year101.23%
EBIT Next 3Y36.56%
EBIT Next 5Y25.33%
FCF growth 1Y123.33%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y6.61%
OCF growth 3Y4.07%
OCF growth 5Y20.79%

SARTORIUS AG-VORZUG / SRT3.DE FAQ

What is the ChartMill fundamental rating of SARTORIUS AG-VORZUG (SRT3.DE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SRT3.DE.


Can you provide the valuation status for SARTORIUS AG-VORZUG?

ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS AG-VORZUG (SRT3.DE). This can be considered as Overvalued.


Can you provide the profitability details for SARTORIUS AG-VORZUG?

SARTORIUS AG-VORZUG (SRT3.DE) has a profitability rating of 3 / 10.


What is the valuation of SARTORIUS AG-VORZUG based on its PE and PB ratios?

The Price/Earnings (PE) ratio for SARTORIUS AG-VORZUG (SRT3.DE) is 46.99 and the Price/Book (PB) ratio is 6.3.


Can you provide the financial health for SRT3 stock?

The financial health rating of SARTORIUS AG-VORZUG (SRT3.DE) is 1 / 10.